Artículo
Current Status of CAR-T Cell Therapy in Multiple Myeloma
Autor/es | Reguera-Ortega, Juan Luis
García-Guerrero, Estefanía Pérez Simón, José Antonio ![]() ![]() ![]() ![]() ![]() |
Departamento | Universidad de Sevilla. Departamento de Medicina Instituto de Biomedicina de Sevilla (IBIS) |
Fecha de publicación | 2021-10-21 |
Fecha de depósito | 2024-05-03 |
Publicado en |
|
Resumen | Current data on CAR-T cell-based therapy is really promising in multiple myeloma,
especially in terms of response. In heavily pretreated patients, who have already received proteasome
inhibitors, immunomodulatory drugs ... Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remission rates. Data are less encouraging in terms of duration of response, although most recent trials have shown significant improvements in terms of event-free survival, with medians ranging from 8 to 14 months and up to 77% progression-free survival at 12 months with an acceptable toxicity profile. These data will be consolidated in future years and will provide new evidence on the best timing for CAR-T cell therapy. Moreover, new CAR-T designs are underway and will challenge the current results. |
Cita | Reguera-Ortega, J.L., García-Guerrero, E. y Pérez Simón, J.A. (2021). Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato, 2 (4), 660-671. https://doi.org/10.3390/hemato2040043. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Currents Status...pdf | 264.6Kb | ![]() | Ver/ | |